Medication Monitor



Generic Name (Trade Name—Company)
Notes
March 26, 2018

Lidocaine 1.8% topical patch

(ZTlido—Scilex Pharmaceuticals/Sorrento)
FDA approves lidocaine 1.8% topical patch for postherpetic neuralgia pain

FDA has approved lidocaine 1.8% topical patch to relieve pain associated with postherpetic neuralgia.

The product contains 36 mg of lidocaine versus 700 mg in the 5% lidocaine patch, including more efficient delivery of lidocaine, superior adhesion, and less residual left in the patch after normal use, according to the manufacturer.

The patch can be worn for 12 hours with effective delivery of the medication, including during exercise.

The agent will become available on the market in 2018.